AlphaCentric Life Sciences and Healthcare FundLYFIX
Type
Mutual fund
Peer group
Global equity
Net assets
$39.3M
Expense ratio
1.46%
1-year return
+24.1%
3 years, a year
+8.5%
5 years, a year
+5.2%
Holdings
63
What it aims to do.
The Fund?s investment objective is long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| First American Funds Inc. | 7.72% |
| GILD Gilead Sciences Inc. | 7.18% |
| AZN AstraZeneca PLC | 5.63% |
| VRTX Vertex Pharmaceuticals Incorporated | 5.60% |
| IONS Ionis Pharmaceuticals, Inc. | 3.74% |
| INSM Insmed Inc | 3.57% |
| INCY Incyte Corporation. | 3.41% |
| ROIV Roivant Sciences Ltd | 3.36% |
| ARGX Argenx SE | 3.33% |
| NBIX Neurocrine Biosciences Inc | 3.22% |
More on LYFIX.
- LYFIX overview
- LYFIX holdings
- LYFIX risk
- LYFIX costs
- LYFIX money in and out
- LYFIX share classes
- Compare LYFIX with other funds
Returns after fees, from the fund's SEC filings up to Mar 2026. Past returns are not a promise. Not financial advice.